Genzyme Bets Big on Biosurgery
Executive Summary
Genzyme Corp is merging two of its subsidiaries, Genzyme Tissue Repair and Genzyme Surgical with a third company, Biomatrix Inc. in a bold bet on the promise of biosurgery--the combination of biomaterials and gene and cellular therapies with more traditional surgical instruments. Clinically, biosurgery will hopefully improve patient outcomes; commercially, it will differentiate surgical instrument makers whose products seem increasingly alike.
You may also be interested in...
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
QUOTED. 22 January 2021. Neil Moat.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
Need a specific report? 1000+ reports available
Buy Reports